Cellectis EPS beats by $0.17, beats on revenue
- BySeeking Alpha-
Cytovia Therapeutics and Cellectis, a clinical stage cell therapy company announced a $760 million research and development collaboration to develop TALEN gene edited iPSC NK and...
Cytovia Therapeutics and Cellectis (CLLS) collaborate to develop TALEN gene-edited iPSC NK and CAR-NK cells. Read more for financial details of the deal.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 7.10 | 7.10 | 6.85 | +0.05 | +0.71% | 26.50M | Lagos | |||
| 160.20 | 160.20 | 160.20 | -9.80 | -5.76% | 643.20K | Lagos | |||
| 31.20 | 31.05 | 30.90 | -0.50 | -1.59% | 20.83M | Lagos | |||
| 25.30 | 25.40 | 24.95 | 0.00 | 0.00% | 46.85M | Lagos | |||
| 7.95 | 7.95 | 7.85 | 0.00 | 0.00% | 23.30M | Lagos | |||
| 7.90 | 7.85 | 7.70 | +0.10 | +1.28% | 10.47M | Lagos | |||
| 16.90 | 16.90 | 16.40 | +0.40 | +2.42% | 1.98M | Lagos | |||
| 22.20 | 22.20 | 21.80 | +2.00 | +9.90% | 1.65M | Lagos | |||
| 2.65 | 3.00 | 2.65 | -0.25 | -8.62% | 4.05M | Lagos | |||
| 5.85 | 5.85 | 5.85 | 0.00 | 0.00% | 157.82K | Lagos | |||
| 0.81 | 0.00 | 0.00 | -0.020 | -2.41% | 19.63M | Lagos | |||
| 5.72 | 5.99 | 5.70 | -0.280 | -4.67% | 19.23M | Lagos | |||
| 44.00 | 44.00 | 44.00 | +4.00 | +10.00% | 82.37K | Lagos | |||
| 5.20 | 5.20 | 5.20 | +0.10 | +1.96% | 186.08K | Lagos | |||
| 1,310.10 | 1,310.10 | 1,310.10 | -39.90 | -2.96% | 48.86K | Lagos |
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.